CIDeRplusGeneral Information:
| Id: | 3,957 |
| Diseases: |
Diabetes mellitus, type II
- [OMIM]
Insulin resistance |
| Homo sapiens | |
| male | |
| article | |
| Reference: | Suhre K et al.(2010) Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting PLoS ONE 5 [PMID: 21085649] |
Interaction Information:
| Comment | The strongest positive associations with diabetes are observed for the numerous sugar metabolites that were observed on the three platforms. Concentrations of glucose, mannose, desoxyhexose (primarily deoxyglucose), uronic acid (primarily glucuronic acid), dihexose (primarily maltose), and several products from the biosynthesis or the degradation of glycosylated proteins or glycolipids (H3-HNAc2-NANA, HNAC, HNAc-H2-dH) are all found increased by up to 90% in the diabetes group. There is a significant decrease of average 1,5-anhydroglucitol concentrations by 37.8% in participants with diabetes when compared to the control group. |
|
Formal Description Interaction-ID: 40168 |
|
| Comment | The strongest positive associations with diabetes are observed for the numerous sugar metabolites that were observed on the three platforms. Concentrations of glucose, mannose, desoxyhexose (primarily deoxyglucose), uronic acid (primarily glucuronic acid), dihexose (primarily maltose), and several products from the biosynthesis or the degradation of glycosylated proteins or glycolipids (H3-HNAc2-NANA, HNAC, HNAc-H2-dH) are all found increased by up to 90% in the diabetes group. There is a significant decrease of average 1,5-anhydroglucitol concentrations by 37.8% in participants with diabetes when compared to the control group. |
|
Formal Description Interaction-ID: 40172 |
|
| Comment | The strongest positive associations with diabetes are observed for the numerous sugar metabolites that were observed on the three platforms. Concentrations of glucose, mannose, desoxyhexose (primarily deoxyglucose), uronic acid (primarily glucuronic acid), dihexose (primarily maltose), and several products from the biosynthesis or the degradation of glycosylated proteins or glycolipids (H3-HNAc2-NANA, HNAC, HNAc-H2-dH) are all found increased by up to 90% in the diabetes group. There is a significant decrease of average 1,5-anhydroglucitol concentrations by 37.8% in participants with diabetes when compared to the control group. |
|
Formal Description Interaction-ID: 40173 |
disease increases_quantity of drug/chemical compound Deoxyhexose |
| Comment | The strongest positive associations with diabetes are observed for the numerous sugar metabolites that were observed on the three platforms. Concentrations of glucose, mannose, desoxyhexose (primarily deoxyglucose), uronic acid (primarily glucuronic acid), dihexose (primarily maltose), and several products from the biosynthesis or the degradation of glycosylated proteins or glycolipids (H3-HNAc2-NANA, HNAC, HNAc-H2-dH) are all found increased by up to 90% in the diabetes group. There is a significant decrease of average 1,5-anhydroglucitol concentrations by 37.8% in participants with diabetes when compared to the control group. |
|
Formal Description Interaction-ID: 40174 |
disease increases_quantity of drug/chemical compound |
| Comment | The strongest positive associations with diabetes are observed for the numerous sugar metabolites that were observed on the three platforms. Concentrations of glucose, mannose, desoxyhexose (primarily deoxyglucose), uronic acid (primarily glucuronic acid), dihexose (primarily maltose), and several products from the biosynthesis or the degradation of glycosylated proteins or glycolipids (H3-HNAc2-NANA, HNAC, HNAc-H2-dH) are all found increased by up to 90% in the diabetes group. There is a significant decrease of average 1,5-anhydroglucitol concentrations by 37.8% in participants with diabetes when compared to the control group. |
|
Formal Description Interaction-ID: 40176 |
|
| Drugbank entries | Show/Hide entries for |
| Comment | The strongest positive associations with diabetes are observed for the numerous sugar metabolites that were observed on the three platforms. Concentrations of glucose, mannose, desoxyhexose (primarily deoxyglucose), uronic acid (primarily glucuronic acid), dihexose (primarily maltose), and several products from the biosynthesis or the degradation of glycosylated proteins or glycolipids (H3-HNAc2-NANA, HNAC, HNAc-H2-dH) are all found increased by up to 90% in the diabetes group. There is a significant decrease of average 1,5-anhydroglucitol concentrations by 37.8% in participants with diabetes when compared to the control group. |
|
Formal Description Interaction-ID: 40182 |
disease increases_quantity of drug/chemical compound H3-HNAc2-NANA |
| Comment | The strongest positive associations with diabetes are observed for the numerous sugar metabolites that were observed on the three platforms. Concentrations of glucose, mannose, desoxyhexose (primarily deoxyglucose), uronic acid (primarily glucuronic acid), dihexose (primarily maltose), and several products from the biosynthesis or the degradation of glycosylated proteins or glycolipids (H3-HNAc2-NANA, HNAC, HNAc-H2-dH) are all found increased by up to 90% in the diabetes group. There is a significant decrease of average 1,5-anhydroglucitol concentrations by 37.8% in participants with diabetes when compared to the control group. |
|
Formal Description Interaction-ID: 40183 |
|
| Comment | The strongest positive associations with diabetes are observed for the numerous sugar metabolites that were observed on the three platforms. Concentrations of glucose, mannose, desoxyhexose (primarily deoxyglucose), uronic acid (primarily glucuronic acid), dihexose (primarily maltose), and several products from the biosynthesis or the degradation of glycosylated proteins or glycolipids (H3-HNAc2-NANA, HNAC, HNAc-H2-dH) are all found increased by up to 90% in the diabetes group. There is a significant decrease of average 1,5-anhydroglucitol concentrations by 37.8% in participants with diabetes when compared to the control group. |
|
Formal Description Interaction-ID: 40184 |
|
| Comment | The strongest positive associations with diabetes are observed for the numerous sugar metabolites that were observed on the three platforms. Concentrations of glucose, mannose, desoxyhexose (primarily deoxyglucose), uronic acid (primarily glucuronic acid), dihexose (primarily maltose), and several products from the biosynthesis or the degradation of glycosylated proteins or glycolipids (H3-HNAc2-NANA, HNAC, HNAc-H2-dH) are all found increased by up to 90% in the diabetes group. There is a significant decrease of average 1,5-anhydroglucitol concentrations by 37.8% in participants with diabetes when compared to the control group. |
|
Formal Description Interaction-ID: 40185 |
disease decreases_quantity of drug/chemical compound |
| Comment | Among the numerous glycerophospholipids that are determined on the Biocrates platform, the phosphatidylcholines PC_aa_C34:4 and the lyso-phosphocholine PC_a_20:4 display marked negative associations with diabetes, followed by many other PC-species with poly-unsaturated fatty acids (PUFAs) in their lipid side chains, although with lower, but still significant strengths of association (PC_ae_C40:1, PC_ae_C36:3, PC_ae_C38:5). |
|
Formal Description Interaction-ID: 40186 |
disease decreases_quantity of drug/chemical compound PC aa C34:4 |
| Comment | Among the numerous glycerophospholipids that are determined on the Biocrates platform, the phosphatidylcholines PC_aa_C34:4 and the lyso-phosphocholine PC_a_20:4 display marked negative associations with diabetes, followed by many other PC-species with poly-unsaturated fatty acids (PUFAs) in their lipid side chains, although with lower, but still significant strengths of association (PC_ae_C40:1, PC_ae_C36:3, PC_ae_C38:5). |
|
Formal Description Interaction-ID: 40201 |
|
| Comment | Among the numerous glycerophospholipids that are determined on the Biocrates platform, the phosphatidylcholines PC_aa_C34:4 and the lyso-phosphocholine PC_a_20:4 display marked negative associations with diabetes, followed by many other PC-species with poly-unsaturated fatty acids (PUFAs) in their lipid side chains, although with lower, but still significant strengths of association (PC_ae_C40:1, PC_ae_C36:3, PC_ae_C38:5). |
|
Formal Description Interaction-ID: 40202 |
disease decreases_quantity of drug/chemical compound PC ae C40:1 |
| Comment | Among the numerous glycerophospholipids that are determined on the Biocrates platform, the phosphatidylcholines PC_aa_C34:4 and the lyso-phosphocholine PC_a_20:4 display marked negative associations with diabetes, followed by many other PC-species with poly-unsaturated fatty acids (PUFAs) in their lipid side chains, although with lower, but still significant strengths of association (PC_ae_C40:1, PC_ae_C36:3, PC_ae_C38:5). |
|
Formal Description Interaction-ID: 40203 |
disease decreases_quantity of drug/chemical compound PC ae C36:3 |
| Comment | Among the numerous glycerophospholipids that are determined on the Biocrates platform, the phosphatidylcholines PC_aa_C34:4 and the lyso-phosphocholine PC_a_20:4 display marked negative associations with diabetes, followed by many other PC-species with poly-unsaturated fatty acids (PUFAs) in their lipid side chains, although with lower, but still significant strengths of association (PC_ae_C40:1, PC_ae_C36:3, PC_ae_C38:5). |
|
Formal Description Interaction-ID: 40204 |
disease decreases_quantity of drug/chemical compound PC ae C38:5 |
| Comment | On the other hand, phosphatidylethanolamines with similar lipid side chain compositions (PE_aa_C34:2, PE_aa_C36:2, PE_aa_C38:4) display an increase in the diabetes group. For example, statistically significant associations are observed in particular when ratios with beta-hydroxyisovalerate are considered. |
|
Formal Description Interaction-ID: 40205 |
disease increases_quantity of drug/chemical compound PE aa C34:2 |
| Comment | On the other hand, phosphatidylethanolamines with similar lipid side chain compositions (PE_aa_C34:2, PE_aa_C36:2, PE_aa_C38:4) display an increase in the diabetes group. For example, statistically significant associations are observed in particular when ratios with beta-hydroxyisovalerate are considered. |
|
Formal Description Interaction-ID: 40206 |
disease increases_quantity of drug/chemical compound PE aa C36:2 |
| Comment | On the other hand, phosphatidylethanolamines with similar lipid side chain compositions (PE_aa_C34:2, PE_aa_C36:2, PE_aa_C38:4) display an increase in the diabetes group. For example, statistically significant associations are observed in particular when ratios with beta-hydroxyisovalerate are considered. |
|
Formal Description Interaction-ID: 40207 |
disease increases_quantity of drug/chemical compound PE aa C38:4 |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40208 |
disease decreases_quantity of drug/chemical compound |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40210 |
disease decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40211 |
disease decreases_quantity of drug/chemical compound |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40212 |
disease decreases_quantity of drug/chemical compound |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40213 |
disease decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40215 |
disease increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40216 |
disease increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40217 |
disease increases_quantity of drug/chemical compound 2-Hydroxypalmitate |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40218 |
disease increases_quantity of drug/chemical compound Heptadecanoic acid |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40219 |
disease increases_quantity of drug/chemical compound 10-Heptadecenoate |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40221 |
disease increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40222 |
disease increases_quantity of drug/chemical compound 2-Hydroxystearate |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40223 |
|
| Drugbank entries | Show/Hide entries for |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40225 |
disease increases_quantity of drug/chemical compound |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40227 |
disease increases_quantity of drug/chemical compound Linoleamide |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40228 |
disease increases_quantity of drug/chemical compound Linolenic acid |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40229 |
disease increases_quantity of drug/chemical compound Eicosenoic acid |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40230 |
disease increases_quantity of drug/chemical compound Dihomo-alpha-linolenate |
| Comment | Concentrations of mediumchain length fatty acids and arachidonate are on average lower in the diabetes group, while other long chain fatty acids are higher, including a number of PUFAs, such as the essential fatty acids linolate and linolenate. Note in particular that arachidonate is incorporated into the lipid side chains of (lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4. |
|
Formal Description Interaction-ID: 40231 |
disease increases_quantity of drug/chemical compound |
| Comment | The branched chain amino acids (BCAAs) leucine, isoleucine, and valine as well as their gamma-glutamyl-derivates are all increased in the diabetes group. |
|
Formal Description Interaction-ID: 40232 |
|
| Comment | The branched chain amino acids (BCAAs) leucine, isoleucine, and valine as well as their gamma-glutamyl-derivates are all increased in the diabetes group. |
|
Formal Description Interaction-ID: 40233 |
|
| Comment | The branched chain amino acids (BCAAs) leucine, isoleucine, and valine as well as their gamma-glutamyl-derivates are all increased in the diabetes group. |
|
Formal Description Interaction-ID: 40234 |
|
| Comment | The branched chain amino acids (BCAAs) leucine, isoleucine, and valine as well as their gamma-glutamyl-derivates are all increased in the diabetes group. |
|
Formal Description Interaction-ID: 40235 |
|
| Comment | The branched chain amino acids (BCAAs) leucine, isoleucine, and valine as well as their gamma-glutamyl-derivates are all increased in the diabetes group. |
|
Formal Description Interaction-ID: 40236 |
|
| Comment | The branched chain amino acids (BCAAs) leucine, isoleucine, and valine as well as their gamma-glutamyl-derivates are all increased in the diabetes group. |
|
Formal Description Interaction-ID: 40238 |
|
| Comment | Highly increased concentrations of the ketone body 3-hydroxybutyrate (BHBA) were observed in the diabetes group. |
|
Formal Description Interaction-ID: 40240 |
disease increases_quantity of drug/chemical compound |
| Comment | Kynurenine levels were found to be 14.6%-21.8% higher in the diabetes group. |
|
Formal Description Interaction-ID: 40242 |
|
| Comment | Erythritol, a naturally-derived sugar substitute, was found to be associated with diabetes in ratios with cysteine (higher erythritol, lower cysteine). The association with erythritol could indicate a more frequent use of sweetener by patients with diabetes. |
|
Formal Description Interaction-ID: 86444 |
|
| Comment | Erythritol, a naturally-derived sugar substitute, was found to be associated with diabetes in ratios with cysteine (higher erythritol, lower cysteine). The association with erythritol could indicate a more frequent use of sweetener by patients with diabetes. |
|
Formal Description Interaction-ID: 86447 |
|
| Drugbank entries | Show/Hide entries for |